Global sales of drugs aimed at treating sexual dysfunction currently mainly include erectile dysfunction and premature ejaculation and was estimated at approximately SEK 50 billion in 2018 with an increase of 1 percent per year between 2018 and 2022.

The most common drugs used to treat erectile dysfunction, PDE5 inhibitors, which include Viagra, were revolutionary when they first arrived on the market in the late 1990s, but they have their limitations, and the market has evolved since then. There is a clear need for new pharmaceuticals that provide a longer lasting effect, fewer side effects and that provide treatment to those patients that are not currently helped by PDE5 inhibitors.

There are today few effective treatments for premature ejaculation introduced to the market.

Dicot's drug candidate is intended to be marketed towards the treatment of both dysfunctions, both separately and in combination. As far as Dicot is aware, simultaneous treatment of both conditions would be unique.